Buparlisib (BKM120, NVP-BKM120)

目录号：S2247

Buparlisib (BKM120, NVP-BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Phase 2。

规格 价格 库存 购买数量  
RMB 2227.95 现货
RMB 1400.12 现货
RMB 2607.65 现货
RMB 7928.28 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck该产品发表文献41篇：

客户使用该产品的6个实验数据：

  • NLGN3 mRNA expression in SU-pcGBM2 cells after 12 hr exposure to vehicle, 50 nM NLGN3, 100 nM BKM120, or 50 nM NLGN3 + 100 nM BKM120.

    Cell, 2017, 161(4):803-16. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Western blot analysis of cleaved caspase 3 in T cell-enriched PBMCs.

    J Hematol Oncol, 2016, 9(1):113. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • AN3CA (A) and JHUEM2 (B) cells were treated for the indicated times with DMSO, 0.3 μM BGJ398 (BGJ), 0.3 μM GDC-0941 (GDC), 0.6 μM BYL719 (BYL) and 0.6 μM BKM120 (BKM) alone or in combination. Cell lysates were immunoblotted with antibodies for phospho-AKT (Ser473), total AKT, phospho-ERK (Thr202/Tyr204), ERK2, phospho-S6 (Ser240/244), total S6, phospho-4EBP1 (Thr37/46), total 4EBP1, total PARP and cleaved PARP. Tubulin was detected as the loading control. Western blot analysis of AN3CA and JHUEM2.

    Mol Cancer Ther, 2017, 16(4):637-648. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of BKM120 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • One customer. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Dr. Pilar Eroles of INCLIVA Biomedical Research Institute.. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Phase 2。
特性 BKM120是可用于口服的生物有效的PI3K抑制剂。
靶点
p110α [1]
(Cell-free assay)		 p110δ [1]
(Cell-free assay)		 p110β [1]
(Cell-free assay)		 p110γ [1]
(Cell-free assay)		 Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
体外研究

BKM120作用于解除PI3K调节的细胞系，包括A2780, U87MG, MCF7和DU145时，具有抗增殖活性，GI50为0.1-0.7 nM。[1] BKM120诱导多发性骨髓瘤细胞(ARP1, ARK, MM.1S, MM1.R和U266)凋亡，导致G1期细胞增多，S期细胞减少。BKM120诱导CD138+原代MM 细胞凋亡，且作用于CD138−基质细胞时毒性较低。BKM120可引起BimS的上调和XIAP的下调。[2]BKM120作用于人类胃癌细胞系，降低mTOR下游信号，具有抗增殖活性。BKM120作用于KRAS突变的胃癌细胞系，可以增强p-ERK或 p-STAT3。BKM120 和STAT3阻断剂联用, 作用于含突变KRAS的细胞，诱导凋亡，具有协同效应，但是作用于KRAS野生型细胞没有这种效果。[3]BKM120主要通过Aurora B激酶调节有丝分裂崩坏。[4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MVnDfZRwfG:6aXOgRZN{[Xl? MVm3NkBp M1TkUGROW09? NXvWR3JJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCneIDy[ZN{cW6pIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQhf2m2aDDHTVUxKG:oIECuNFAxOTV6IN88US=> M2H0OVI1QTByMk[2
DU145 NFnrNZBEgXSxdH;4bYMhSXO|YYm= M1;0e|czKGh? MXHEUXNQ MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BmgHC{ZYPzbY5oKEyNQkGgcZV1[W62IIfpeIghT0l3MDDv[kAxNjByMESzOUDPxE1? NUnhXVNGOjR7MECyOlY>
A2780 NVnJSmVpS3m2b4TvfIlkKEG|c3H5 M1HKOVczKGh? MoDESG1UVw>? MkDVR5l1d3SxeHnjbZR6KGGpYXnud5QhWFSHTj3k[YZq[2mnboSgbJVu[W5iQUK3PFAh[2WubIOge4l1cCCJSUWwJI9nKDBwMECwOlM2KM7:TR?= NFH5NGgzPDlyMEK2Oi=>
U87MG NWC3V49OS3m2b4TvfIlkKEG|c3H5 NUKzRok{PzJiaB?= Mn70SG1UVw>? MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBRXEWQLXTl[olkcWWwdDDoeY1idiCXOEfNS{Bk\WyuczD3bZRpKEeLNUCgc4YhOC5yMEC2PVgh|ryP NUf1ZXdOOjR7MECyOlY>
A2780 NXvMbXVyTnWwY4Tpc44hSXO|YYm= NF\EWWoyKGh? MnrISG1UVw>? M2f3PGlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6wOVUh|ryP MVGyOFkxODJ4Nh?=
DU145 MVXGeY5kfGmxbjDBd5NigQ>? NH6ybJQyKGh? M4ezUGROW09? NHjQ[VBKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hTFVzNEWgZ4VtdHNiaHHyZo9zcW6pIFzLRlEhdXW2YYTpc44hf2m2aDDFR|UxKG:oIECuNFc{KM7:TR?= MWqyOFkxODJ4Nh?=
A2780 MWfGeY5kfGmxbjDBd5NigQ>? Mke0NUBp MV7EUXNQ MmT5TY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKFCWRV6t[IVncWOrZX70JIh2dWGwIFGyO|gxKGOnbHzzJJdqfGhiRVO1NEBw\iByLkC3OEDPxE1? NHKzUWQzPDlyMEK2Oi=>
MCF7 MUXGeY5kfGmxbjDBd5NigQ>? NUPMZYh4OSCq NHvvVJVFVVOR MXrJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCHNUS1T{BufXSjboStcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMTFOwG0> NGDWclUzPDlyMEK2Oi=>
U87MG NWi1bYRKTnWwY4Tpc44hSXO|YYm= Mn;nNUBp NWDHN3h1TE2VTx?= NWi5coo6UW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJHU5P02JIHPlcIx{KHerdHigSWM2OCCxZjCwMlE{KM7:TR?= NF;iUmUzPDlyMEK2Oi=>
A2780 M33Zb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVm3NkBp M1TtfGROW09? MY\FR|UxRTBwNUKg{txO NV\JSIVZOjR7MECyOlY>
SKMES-1 MV;DfZRwfG:6aXOgRZN{[Xl? NGHXOJMyKM7:TR?= NYroeHBIPzJiaB?= MlPUTY5lfWOnczDj[YxtKGSnYYTo M1vYRVI3ODF|M{G4
H596 MUjGeY5kfGmxbjDBd5NigQ>? MoS4NUDPxE1? MVfJcZBicXK|IHPlcIwhdWmpcnH0bY9v NH:yU44zPjBzM{OxPC=>
HCC2450 Mkf0SpVv[3Srb36gRZN{[Xl? MVuxJO69VQ>? MVPJcZBicXK|IHPlcIwhcW64YYPpc44> NGDORXgzPjBzM{OxPC=>
A549 MXTGeY5kfGmxbjDBd5NigQ>? Ml3XOVAxKG6P M4PHPFQ5KGh? NWW4eVJNTE2VTx?= Mn20TY5pcWKrdIOgRYt1KGGldHn2ZZRqd25? MmHzNlU6Ozd{OUm=
A549 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOyTncyOSEQvF2= M3jtR|czKGh? M4D0TWROW09? MYnJcohq[mm2czDj[YxtKGe{b4f0bC=> M2G3fVI2QTN5Mkm5
H522 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV2xJO69VQ>? M3nz[FczKGh? NX3SPIVpTE2VTx?= NYG3bm94UW6qaXLpeJMh[2WubDDndo94fGh? M3TTS|I2QTN5Mkm5
LNCaP MnS3SpVv[3Srb36gRZN{[Xl? MVmxJO69VQ>? MVzTeZBxemW|c3XzJJAuSUuWIHzleoVtew>? M1PWS|I2OzZyN{m5
LNCaP95 MWjGeY5kfGmxbjDBd5NigQ>? M4n0V|Eh|ryP NXriSnNOW3WycILld5NmeyCyLVHLWEBt\X[nbIO= NEjt[YUzPTN4MEe5PS=>
HCT-15 MWTBdI91d3OrczDBd5NigQ>? NFTjSYQyOCEQvF2= NF7sfo81QCCq M3\iSGROW09? MmjqTY5lfWOnczDhdI9xfG:|aYOgbY4hUEOWLUG1JINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? MnPUNlUyPTJ{NEW=
HCT-116 MoDwRZBwfG:|aYOgRZN{[Xl? NIPse4IyOCEQvF2= MUe0PEBp NXzrTXVsTE2VTx?= NECxfY9KdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVE3KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= M{TKU|I2OTV{MkS1
NCI-H460 NY[0UZoxSXCxdH;zbZMhSXO|YYm= MXmxNEDPxE1? MUG0PEBp Mn\OSG1UVw>? MWfJcoR2[2W|IHHwc5B1d3OrczDpckBPS0lvSES2NEBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w M2L4WFI2OTV{MkS1
SKOV-3 M4X2cWFxd3Sxc3nzJGF{e2G7 MUSxNEDPxE1? M3fRVFQ5KGh? NFfTZ4ZFVVOR MkLkTY5lfWOnczDhdI9xfG:|aYOgbY4hW0uRVj2zJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? MlnZNlUyPTJ{NEW=
BSY-1 MmjuRZBwfG:|aYOgRZN{[Xl? M2\2cFExKM7:TR?= MUm0PEBp NXzEXoZVTE2VTx?= M{T2cmlv\HWlZYOgZZBweHSxc3nzJIlvKEKVWT2xJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? MWiyOVE2OjJ2NR?=
MKN-1 NWHLUnl[SXCxdH;zbZMhSXO|YYm= MljINVAh|ryP NGTZ[2k1QCCq NI\kbZpFVVOR M4POdGlv\HWlZYOgZZBweHSxc3nzJIlvKE2NTj2xJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? NYTnZ2c2OjVzNUKyOFU>
NCI-H522 M{DnXGFxd3Sxc3nzJGF{e2G7 NHjWPFYyOCEQvF2= NInMToQ1QCCq M3TpVmROW09? MWDJcoR2[2W|IHHwc5B1d3Orcx?= M4nB[|I2OTV{MkS1
OVCAR-3 M4K0SmFxd3Sxc3nzJGF{e2G7 NUPpVJREOTBizszN MXy0PEBp NVLTNY9tTE2VTx?= NWjuOVF[UW6mdXPld{BieG:ydH;zbZM> MX2yOVE2OjJ2NR?=
HBC-5 M1XWOWFxd3Sxc3nzJGF{e2G7 Mn;KNVAh|ryP NHu3bZo1QCCq MnrqSG1UVw>? NUW1fYkxUW6mdXPld{BieG:ydH;zbZM> Moe5NlUyPTJ{NEW=
RXF-631L NYqweYdsSXCxdH;zbZMhSXO|YYm= M2LL[FExKM7:TR?= MWG0PEBp NIXIWVNFVVOR NGO2fmNKdmS3Y3XzJIFxd3C2b4Ppdy=> MYWyOVE2OjJ2NR?=
MKN-45 M3vjVWFxd3Sxc3nzJGF{e2G7 NVPJb4gxOTBizszN NX72V5F2PDhiaB?= NX3JcVAyTE2VTx?= NWPsdGZQUW6mdXPld{BieG:ydH;zbZM> MYCyOVE2OjJ2NR?=
BON-1 MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVq1NFAhdk1? NI\iRoUyOCCm M1LKSGROW09? NVTKWHJ6UW6qaXLpeJMh[2WubDDndo94fGh? NYfaO4VkOjVyMk[yPVI>
BON-1 NXrR[pZMTnWwY4Tpc44hSXO|YYm= NV72dFBwPTByIH7N M3PQclQhcA>? MUXEUXNQ M3vhS2lvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgWIhzOzB6IHHu[EBU\XJ2N{O= M2POXVI2ODJ4Mkmy
QGP-1 NH70VW5HfW6ldHnvckBCe3OjeR?= MXq1NFAhdk1? NHjZRpM1KGh? M1Hwe2ROW09? M1TzU2lvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgWIhzOzB6IHHu[EBU\XJ2N{O= M{TScVI2ODJ4Mkmy
Huh7 M{frR2Z2dmO2aX;uJGF{e2G7 NYfsbHNDOSEQvF2= M2nlcVEhcA>? NEWzS2lFVVOR MnS2TY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDT[ZI1PzR? MViyOVAxPDRyMx?=
BNL Mm[2SpVv[3Srb36gRZN{[Xl? NH;6RpoyKM7:TR?= MYixJIg> M{\vVWROW09? MXPJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gV|Y> Moq2NlUxODR2MEO=
MDA-MB-175 NFno[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[2Z|Eh|ryP MUK1JIQ> MXTEUXNQ M2X3eGlEPTB:MTFOwG0> MWSyOFg4QTd7Nh?=
MDA-MB-134 NIrVeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHqyO5YyKM7:TR?= M4D0ZVUh\A>? NWXyU5NpTE2VTx?= NEO4dpJKSzVyPEGg{txO NInRZlgzPDh5OUe5Oi=>
HCC1500 MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L4UlEh|ryP MnqyOUBl NF\DepBFVVOR NU\QPFlzUUN3MEyxJO69VQ>? NX3lXnUxOjR6N{m3PVY>
EFM-19 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3MXGgyKM7:TR?= NHvYe2k2KGR? MkLSSG1UVw>? NX7UOnZ6UUN3MEyxJO69VQ>? M13pdlI1QDd7N{m2
ZR-75-30 MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrQUFYyKM7:TR?= M1vC[|Uh\A>? MkHBSG1UVw>? NHPrdGlKSzVyPEGg{txO Mm\pNlQ5Pzl5OU[=
MDA-MB-361 NYG0N5dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnISVEyKM7:TR?= NEjCcVU2KGR? NFHOT3VFVVOR MnvaTWM2ODxzIN88US=> NXPKSXpsOjR6N{m3PVY>
T-47D M2TCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:xJO69VQ>? NGjTfW82KGR? M{fJ[GROW09? M3jNRmlEPTB:MTFOwG0> NEjBXVgzPDh5OUe5Oi=>
SK-BR-3 NYfMPFRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7kU2YyKM7:TR?= NWPROppzPSCm NYDp[2NQTE2VTx?= MXLJR|UxRDFizszN NGewNWMzPDh5OUe5Oi=>
UACC-732 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjqfIsyKM7:TR?= MnzWOUBl NInNWJpFVVOR NEX0VW5KSzVyPEGg{txO MmrBNlQ5Pzl5OU[=
BT-474 M13kRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv1NUDPxE1? MoDwOUBl NFTQV|ZFVVOR M3rmN2lEPTB:MTFOwG0> NFvBfHYzPDh5OUe5Oi=>
HCC202 M{TycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYWxJO69VQ>? NIHuO3A2KGR? MXvEUXNQ NFPWXJBKSzVyPEGg{txO NYPHdlNKOjR6N{m3PVY>
MCF7 NEXORpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NISxN5gyKM7:TR?= MVG1JIQ> NXqzSVlvTE2VTx?= MlGzTWM2ODxzIN88US=> NXy2[2dLOjR6N{m3PVY>
MDA-MB-415 M{XyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HzSFEh|ryP MUS1JIQ> MmrBSG1UVw>? NHy1SXBKSzVyPEGg{txO NGn4ZXAzPDh5OUe5Oi=>
MDA-MB-453 M2n1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomxNUDPxE1? MWq1JIQ> MWHEUXNQ M4DtVmlEPTB:MTFOwG0> NWXNWZBGOjR6N{m3PVY>
ZR-75-1 MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv1NUDPxE1? NVPST5dRPSCm NGexVFlFVVOR M4DuOmlEPTB:MTFOwG0> Mk\5NlQ5Pzl5OU[=
HCC38 NIDCZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr4eYoyKM7:TR?= Mn21OUBl NGfpN3hFVVOR MUPJR|UxRDFizszN NWTaWIdbOjR6N{m3PVY>
HCC1419 M{TwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO3SWNZOSEQvF2= Mn3xOUBl M2X0cWROW09? Mkn4TWM2ODxzIN88US=> Ml7aNlQ5Pzl5OU[=
UACC-812 NGHjdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfqc|UyKM7:TR?= MWC1JIQ> Mon4SG1UVw>? MVnJR|UxRDFizszN MoWxNlQ5Pzl5OU[=
HCC1187 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSxJO69VQ>? Mm\hOUBl Ml;XSG1UVw>? NYLCVpZ2UUN3MEyxJO69VQ>? NGeycYozPDh5OUe5Oi=>
KPL-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTLNUDPxE1? M3PsW|Uh\A>? M1jaOmROW09? NWDPb|lpUUN3MEyxJO69VQ>? NH\HSXIzPDh5OUe5Oi=>
SUM-225 NHSxUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVyxJO69VQ>? MUG1JIQ> NWTTR5NKTE2VTx?= NXPjfnZbUUN3MEyxJO69VQ>? M33Ud|I1QDd7N{m2
EFM-192A NXzXXI5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fXb|Eh|ryP M3LMWlUh\A>? M2foU2ROW09? MX\JR|UxRDFizszN M2nqR|I1QDd7N{m2
JIMT-1 NXrEc3k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyxJO69VQ>? NVvOTFJwPSCm NXLvU3diTE2VTx?= NHL3ZZhKSzVyPEGg{txO Mo\CNlQ5Pzl5OU[=
HCC1143 MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[xJO69VQ>? NFj2Z3Q2KGR? M{LEemROW09? MlHqTWM2ODxzIN88US=> M1rDclI1QDd7N{m2
HCC2218 NGHMbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4CxXVEh|ryP NE\Keos2KGR? MVjEUXNQ MofzTWM2ODxzIN88US=> Mly0NlQ5Pzl5OU[=
MDA-MB-468 NGPqSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLYepBNOSEQvF2= MXm1JIQ> NYnQUJppTE2VTx?= MWXJR|UxRDFizszN MXyyOFg4QTd7Nh?=
BT-20 Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fOXlEh|ryP MY[1JIQ> MkDzSG1UVw>? M1LE[mlEPTB:MTFOwG0> M2PuVlI1QDd7N{m2
MDA-MB-435 MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCxJO69VQ>? M2HLXlUh\A>? NFLFPXJFVVOR MmnwTWM2ODxzIN88US=> M37z[|I1QDd7N{m2
BT-549 NHvUUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\mT3dMOSEQvF2= M3;3PVUh\A>? M3f1ZmROW09? MljSTWM2ODxzIN88US=> M{LVXVI1QDd7N{m2
HCC1806 M4TCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV6xJO69VQ>? MWC1JIQ> NYLQWYJETE2VTx?= NGOyd5JKSzVyPEGg{txO NGHjOpkzPDh5OUe5Oi=>
HCC1937 MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnFfHMyKM7:TR?= MkjlOUBl M1HMN2ROW09? MWTJR|UxRDFizszN MljENlQ5Pzl5OU[=
Hs578T NI\B[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M125TlEh|ryP NVvwW5ZpPSCm NHOwUoJFVVOR M2jzT2lEPTB:MTFOwG0> MmLsNlQ5Pzl5OU[=
LN18 NFjTd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;mbndIOjBizszN NILtWo44OiCq NUXnfHZGTE2VTx?= MWHJR|UxRDVizszN MnzINlQ4PDFyN{S=
LN229 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjzNlAh|ryP MkflO|IhcA>? NGHqXJhFVVOR NInCeFlKSzVyPEWg{txO MlPSNlQ4PDFyN{S=
LNZ308 NWXXPJJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj6XWI6OjBizszN MXG3NkBp Mli3SG1UVw>? Mn3nTWM2ODx3IN88US=> MYSyOFc1OTB5NB?=
T98G Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlO2NlAh|ryP M1\YSFczKGh? MoLhSG1UVw>? NEDBWlhKSzVyPEWg{txO MmrnNlQ4PDFyN{S=
U87 NGLQc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P6elIxKM7:TR?= MnnSO|IhcA>? M3XIPWROW09? NUDyfJI4UUN3MEy1JO69VQ>? NIDqd3gzPDd2MUC3OC=>
LN18 NInKbIlHfW6ldHnvckBCe3OjeR?= MlnROUDPxE1? MV:yOEBp MX;EUXNQ NUPyXYRMUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= M1f6[VI1PzRzMEe0
LNZ308 MUTGeY5kfGmxbjDBd5NigQ>? NGfCfmo2KM7:TR?= NVXsXmd5OjRiaB?= MkjtSG1UVw>? MW\Jcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtV MnP3NlQ4PDFyN{S=
Saos-2 NF7vWIVHfW6ldHnvckBCe3OjeR?= NGrRNIk2OCEQvF2= MYW0PEBp NILDOpdKdmirYnn0d{Bk\WyuIHnueoF{cW:w MXKyOFczPzZ4MB?=
MG-63 M3jDVWZ2dmO2aX;uJGF{e2G7 NYP0d2lUPTBizszN NGHoZZk1QCCq MXjJcohq[mm2czDj[YxtKGmwdnHzbY9v NVe1VWdDOjR5Mke2OlA>
SJSA-1 NIji[oNHfW6ldHnvckBCe3OjeR?= M162SlUxKM7:TR?= NGjQPZk1QCCq NYXZTm5jUW6qaXLpeJMh[2WubDDpcpZie2mxbh?= NGTY[HczPDd{N{[2NC=>
Saos-2 NXOwdJpZTnWwY4Tpc44hSXO|YYm= MWq1NEDPxE1? NU\mc4VCPDhiaB?= NWLCdXpoUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? M2noZ|I1PzJ5Nk[w
MG-63 NUHhcY94TnWwY4Tpc44hSXO|YYm= NUPIOpdXPTBizszN NI[2Z2I1QCCq NEjRUG9KdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v MmC3NlQ4Ojd4NkC=
SJSA-1 MXfGeY5kfGmxbjDBd5NigQ>? NHH3eJg2OCEQvF2= NI\hNIs1QCCq M4\Mb2lvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> NWXPclZ6OjR5Mke2OlA>
Saos-2 NHLUNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjjOVAh|ryP M1rzR|Q5KGh? MmLOTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MYOyOFczPzZ4MB?=
MG-63 NULzd|FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV21NEDPxE1? MUG0PEBp NWTacJFSUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MlTpNlQ4Ojd4NkC=
SJSA-1 M3[xdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{GyO|UxKM7:TR?= Mn7QOFghcA>? M2fCS2lvcGmkaYTzJINmdGxidnnhZoltcXS7 M3PqcFI1PzJ5Nk[w
FaDu NHTRPVFHfW6ldHnvckBCe3OjeR?= MVu1JO69VQ>? NXfUcWR4OjRiaB?= MnvFSG1UVw>? NVPWO3pyWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> NYXz[YhKOjR4M{GxOFc>
EMT6 Mn23SpVv[3Srb36gRZN{[Xl? NIe5NHc2KM7:TR?= M2DJZVI1KGh? Mn\USG1UVw>? NHG5bXlT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> Mn6xNlQ3OzFzNEe=
HCT116 M2H5OmZ2dmO2aX;uJGF{e2G7 MXu1JO69VQ>? M1viPVI1KGh? NFW1VJNFVVOR M4WzbXJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u NH[2PVMzPDZ|MUG0Oy=>
U87 NYHNO4FxTnWwY4Tpc44hSXO|YYm= NFfvU|Y2KM7:TR?= MU[yOEBp NUHVUFhqTE2VTx?= NF\EWIVT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> MVWyOFY{OTF2Nx?=
GBM MVTBdI9xfG:|aYOgRZN{[Xl? NGnLVmgz|ryP NFTidZY1QGh? NHnZd29FVVOR NYfLTlg2cW6mdXPl[EBpcWeqZYKgcIV3\Wy|IH;mJIFxd3C2b4Ppd{wh[W6mIHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gQ>? MUOyOFUxODR7Mh?=
BON NFW3PZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nublEuPc7:TR?= NWTrNFFVPzKq NHzFZYJl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v MVWyOFQ1OzV{Mx?=
BON M1W5Z2Fxd3C2b4Ppd{BCe3OjeR?= M4PzVlEuPc7:TR?= NGfQV20zPGh? M4r2Xolv[3KnYYPld{BieG:ydH;zbZM> MXKyOFQ1OzV{Mx?=
H1975 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnCVXkxNjNvOT62{txO Mn\pO|Jp NWjZe3FJTE2VTx?= MVTJR|UxRTFwM{i1{txO NXmzPY91OjR|M{e4OFY>
H1975 MXTBdI9xfG:|aYOgRZN{[Xl? MlTPNu69VQ>? M4O0TlI1cA>? NV32dHM5TE2VTx?= MYHpcoNz\WG|ZYOgZZBweHSxc3nzJJJifGVic3nncolncWOjboTsfS=> Mn;BNlQ{Ozd6NE[=
T-ALL MYXBdI9xfG:|aYOgRZN{[Xl? M4DLRYJmfHenZX6gNU41KGGwZDC1MlMhdU1iYYSgNlRpKGGwZDCwMlkh[W6mIEWuOUBuVSCjdDC0PIghcW5iZHnm[oVz\W62IHPlcIwhdGmwZR?= MlfpNlQhd3JiNEjo NYTlO21LTE2VTx?= NGLxeZhi\m[nY4TzJJRp\SCSSUPLJJBifGi5YYmgbY4hXC2DTFygZ4VtdCCuaX7ldy=> MWCyOFMyODd|Nh?=
BCR-ABL NUHVT4RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYewMlI2NTFyzszN MonzOIQ> NUH5e3Bre2mpbnnmbYNidnSueTDpcohq[mm2IHPlcIwheHKxbHnm[ZJifGmxbh?= NILwdYczPDJ2NE[xNi=>
LC-1/SQSF NUXVOHNWTnWwY4Tpc44hSXO|YYm= Mlm0N:69VQ>? NGG4ZWgzPGh? M1nqdGROW09? M3f4O4Rm[3KnYYPlJG5TTjJicILveIVqdiCuZY\lcC=> M2foVVI{QThyMEmz
Primary CLL cells NEnvbo5CeG:ydH;zbZMhSXO|YYm= NXvEUYVjOS1zMN88US=> MlrWOFhp NIHmZXBqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCFTFygZ4VtdHNiaX7k[ZBmdmSnboSgc4YheHKxZ37vd5Rq[yCvYYLr[ZJ{ NUnuboZuOjN6NUC4NFc>
Primary CLL cells MXPLbY5ie2ViQYPzZZk> M4j4WFLPxE1? M2fDXlMxdWmw M2LqUIRm[3KnYYPl[EBRUTONIHHjeIl3cXS7 MUWyN|g2ODhyNx?=
Primary CLL cells NEHWN2dEgXSxdH;4bYMhSXO|YYm= M3G2T|LPxE1? MoKzNlRp NFTtNVFqdmS3Y3XzJINmdGxiY4n0c5RwgGmlaYT5 NGC0ZngzOzh3MEiwOy=>
human NSCLC cell lines NH30[5lCeG:ydH;zbZMhSXO|YYm= NFfxOGcxNjF{NT20{txO M2PIV|I1cA>? M{nvfWROW09? NYPh[nljUUN3MIOgdoFv\2W|IH\yc40hOC52LUNOwG0> MW[yN|U3OjR5Mh?=
human HCC cell lines M3;2RmNmdGxidnnhZoltcXS7IHHzd4F6 NX;O[GN5OC5yMEWtNe69VQ>? MXi0PIg> NUDU[Y8zUUN3ME2x{txO M{LaWFI{PDh7OUm5
Huh7 NXftdVQ2U2mwYYPlJGF{e2G7 NWflc4J4Oc7:TR?= MUK0PIg> NW\MTIZqe2mpbnpvsKFk[W62bImgdoVlfWOnczDwbI9{eGixconsZZRqd25ib3[gRYt1 MVSyN|Q5QTl7OR?=
SK-HEP1 NFPSPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L1WFEuOjEQvF2= MYW3Nog> MmjHSG1UVw>? M{fjOmlEPTExvKyx{txO NU\GSmdSOjN2N{mxN|Y>
786-0 NUHy[2s{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTPNU0zOM7:TR?= MkW0O|Jp M4r4Z2ROW09? Mn7ZTWM2OO,:nEJOwG0> M1PwfFI{PDd7MUO2
JVM2 NFTNXXVEgXSxdH;4bYNqfHliYYPzZZk> M3\Y[FAvOi1{MN88US=> NYf2dlhlPzKq NFTUUoJFVVOR NVS4[5lkUUN3ME2wMlnPxE1? MXiyN|I{QDZ|OR?=
EHEB NFfY[HZEgXSxdH;4bYNqfHliYYPzZZk> MYCwMlIuOjEQvF2= NXzSO25EPzKq NVrXOnRKTE2VTx?= NUTIVnlXUUN3ME2wMlfPxE1? NFfKWIYzOzJ|OE[zPS=>
MEC2 NYDDbVlmS3m2b4TvfIlkcXS7IHHzd4F6 M4rte|AvOi1{MN88US=> NGm0fYE4Omh? M3viTmROW09? M4ixcmlEPTB;MD63{txO NVz1WlB1OjN{M{i2N|k>
primary B-CLL lymphocytes NUXFN4tRSXCxcITvd4l{KEG|c3H5 NX3kfpFpUUN3MDDmc5Ih\WGlaDDwdolu[XK7IHPlcIwhdGmwZR?= NHn5WYIzPGh? NIizeYtFVVOR M2m5NGlEPTExvKyz{txOKG[xcjDhcIwheGG2aXXueJM> M17QSlI{OjN6NkO5
primary B-CLL lymphocytes M1PwVmtqdmG|ZTDBd5NigQ>? M{WzcWlEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV? MWSyOIg> M4HNZ4lvcGmkaYTzJJA4OFN4SzCmJFRGNUKSMTDlfJBz\XO|aX;u MV6yN|I{QDZ|OR?=
human NSCLC NVT1PJBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LtOVAvPS1{zszN NGPrUpY4Omh? MXjJR|UxRTIQvF2= MViyNlc5OTN7Mx?=
human NSCLC M1;oRmtqdmG|ZTDBd5NigQ>? M3XH[VHPxE1? NXfHXGoyOjSq MUnpcohq[mm2czD0bIUhSWu2L33UU3Ihe2mpbnHsbY5oKHCjdHj3ZZkh[XRiM3igZYZ1\XJidILlZZRu\W62 M1HEN|IzPzhzM{mz
Y1 cell line NX\1NIE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;1UpdrOC5zzszNM|HPxE1? Mo\FNlRp MmrySG1UVw>? NFXlOFlqdmirYnn0d{A3OO,:hTDj[YxtKH[rYXLpcIl1gSCrbjDNfYMuW2O2cj30doFve2[nY4Tl[EBk\Wyucx?= NGnocHozOjZ7MkmwOC=>
PIK3CA-mutant MCF7 Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPnd3NIUTVyPUG2NOKyQTGwTf-8kGxFPTB;OUiwxtEzPzOwTR?= MWq3Nog> NHzubYhIUTVyPUG2NOKyQTGwTf-8kGxFPTB;OUiwxtEzPzOwTR?= NYHTWnFQOjJ4NUO5Olc>
PIK3CA-mutant MCF7 NWi0OZcxU2mwYYPlJGF{e2G7 MmDiTWM2OD1zMUVCtVNvVQ>? MofkO|Jp NYq5fWx7UUN3ME2xNVTDuTOwTTDpckBz\WS3Y3nu[{BCc3RicHjvd5Bpd3K7bHH0bY9vKGyndnXsdy=> Mli4NlI3PTN7Nke=
MCF7-myr-Akt MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D6SmdKPTB;Mkm5xtE3QG6P78{MUGQ2OO,:nkGwMFAxOG6P NGCyTGs4Omh? MkDtS2k2OD1{OUpCtVY5dk4xvJzMSFUx97zgMUCsNFAxdk1? NEnUelIzOjZ3M{m2Oy=>
colon cancer cell lines NYnCR|hNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPnNE0yOM7:TR?= NInJZ2Y4Omh? NHT5WmRFVVOR Ml3oTWM2OD1zzszN NEnDcnAzOjV2M{i1Oy=>
gastric cancer cell lines MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\5TI1OOC1zMN88US=> MWS3Nog> MVrEUXNQ MoixTWM2OD1{LUZOwG0> MXKyNlU1Ozh3Nx?=
HCT-116/HT-29/MKN-45 NXjaVG13SXCxcITvd4l{KEG|c3H5 NW\KU|FbOs7:TR?= NUPDN3lJPDiq MmHEd4hq\nRiaX6gS|IheGijc3W= MmiyNlI2PDN6NUe=
HT-29 and HCT-116 MYPDZZNx[XOnIHHzd4F6 MkXnOe69VQ>? MonHNlRp M3jX[Ilv\HWlZYOgZ4F{eGG|ZTDhZ5Rqfmm2eR?= NGOz[Y8zOjV2M{i1Oy=>
MM cell lines NUL5c3lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDzTlZCOTEQvF2= MUWyOIg> MoPGSG1UVw>? NFzBeXJKSzVyII\hdolmeyCjbX;u[{BlcW[oZYLlcpQh[2WubDDsbY5meyCrbjD0bY1mKGGwZDDkc5NmKGSncHXu[IVv[2V? M4jNbVIzOjB5NEi1
ARP-1 MUHBdI9xfG:|aYOgRZN{[Xl? M4TDSVEx|ryP NWXTbI1oOjSq NYHG[ZB6TE2VTx?= NUPZO|M5cW6mdXPld{BOVSClZXzsJIFxd3C2b4Ppd{B1cHKxdXfoJINie3Cjc3WgZYN1cX[jdHnvci=> MWiyNlIxPzR6NR?=
SNU-601 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rD[FczcA>? MWnEUXNQ NEm5NnlKSzVyPUCuPFE3yrFyLkC2N:69VQ>? M372dlIzOTV7OEG0
SNU-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvTNWE4Omh? NWXaZYc2TE2VTx?= MWTJR|UxRTFwMEiyxtExNjB{ON88US=> MkLaNlIyPTl6MUS=
SNU-668 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7acnc4Omh? M1LrfWROW09? NWSyXYdSUUN3ME2xMlU4QcLzMD6wO|TPxE1? M2XFWlIzOTV7OEG0
AGS NEDDNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrvdmY4Omh? NXTzNppRTE2VTx?= NG[0VppKSzVyPUGuO|E1yrFyLkGxO:69VQ>? MnjoNlIyPTl6MUS=
SNU-216 M{LC[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIewOpM4Omh? NGLlZ2tFVVOR NXTGXWxpUUN3ME2yMlY6OsLzMD6wPFLPxE1? M3vweVIzOTV7OEG0
SNU-5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnDbFZNPzKq MVvEUXNQ NXnpW|FHUUN3ME2xMlM2OcLzMD6wPVHPxE1? NELpR3gzOjF3OUixOC=>
SNU-638 NFn4ZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXy3Nog> NFrMXG5FVVOR NYjVSoJLUUN3ME2yMlI5OsLzMD6wOVPPxE1? NV\hXVNjOjJzNUm4NVQ>
SNU-16 MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PiUlczcA>? M1\TcGROW09? M4D1bmlEPTB;MT61O|PDuTBwMECx{txO NILhOWczOjF3OUixOC=>
SNU-484 M13jUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIWzRY84Omh? NUDtenpNTE2VTx?= M2K3O2lEPTB;MT63NljDuTBwMES1{txO NVj6bGdIOjJzNUm4NVQ>
SNU-620 NInXUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XjUVczcA>? M4XGbWROW09? NF7kUFRKSzVyPUKuPVM6yrFyLkCwNe69VQ>? NHf0RmwzOjF3OUixOC=>
SNU-719 M376dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTGfmlyPzKq NVzJd|B2TE2VTx?= MXTJR|UxRTNwMEO3xtExNjB|Mt88US=> M2DnXVIzOTV7OEG0
glioma cell lines M3;OUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HsSlczcA>? MlT5TWM2OD1zLUNOwG0> NHnqVW4zOjB4NUC4NC=>
U87 M3uxOmFxd3C2b4Ppd{BCe3OjeR?= M3q4dFLPxE1? MXq3Nog> NU[4W3U{cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDhcoQh[2ynYY\l[EBRSVKSIHHu[EBk[XOyYYPlMVM> MXKyNlA3PTB6MB?=

... Click to View More Cell Line Experimental Data
体内研究 BKM120按30, 60, 或100 mg/kg剂量作用于A2780移植瘤，完全抑制pAKTser473。BKM120按 30和 60 mg/kg剂量作用于U87MG神经胶质瘤模型，显示抗癌活性。[1]BKM120每天按5μM/kg剂量处理具有持久生命力的ARP1 SCID鼠模型，导致肿瘤体积和K链水平明显降低。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[2]
+ 展开

PI3K 生化实验(ATP 消耗实验):

BKM120溶于DMSO中，按每孔1.25 µL直接加到黑色384孔板上。开始反应, 25 µL 10nM PI3K和5 µg/mL 1-α-磷酸肌醇(PI)加到实验 buffer (10 mM Tris pH 为7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT，及0.05% CHAPS)，然后加到每孔中，随后在实验buffer中加入25 µL 2 µM ATP。反应进行直到50% ATP被消耗，然后加入25 µL KinaseGlo溶液终止反应。终止的反应温育5分钟，然后通过荧光测定残留的ATP。
细胞实验：[1]
+ 展开
  • Cell lines: A2780细 胞
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3天
  • Method: A2780细胞培养在含10% FBS,L-谷氨酸,丙酮酸钠和抗生素的DMEM培养基上。细胞按每孔103个细胞的密度接种在相同培养基上，温育3到5小时。稀释溶于20 mM DMSO中的BKM120。2 µL稀释的BKM120溶液加到细胞培养基上, (浓度为0-6.6 µM)。等体积(100 µL)溶液加到96孔板中，在37oC下温育3天。使用Trilux读取荧光值而测定抑制细胞增殖的效果
    (Only for Reference)
动物实验：[1]
+ 展开
  • Animal Models: 携带U87MG 和A2780移植瘤的雌性裸鼠
  • Formulation: 15% Captisol
  • Dosages: ~60 mg/kg
  • Administration: 每天口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
5% DMSO+30% PEG 300+ddH2O 		15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 410.39
化学式

C18H21F3N6O2
CAS号 944396-07-0
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02756247 Active not recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02756247 Active not recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02614508 Active not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT02614508 Active not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项
Selleck产品目录册

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

  • Taselisib (GDC 0032) New

    Taselisib (GDC 0032)是一种有效，下一代的β亚型PI3K抑制剂，作用于PI3Kα/δ/γ， IC50分别为0.29 nM/0.12 nM/0.97nM，比作用于PI3Kβ选择性高10倍以上。

  • Pilaralisib (XL147) New

    Pilaralisib (XL147)是一种选择性的可逆I型PI3K抑制剂，作用于PI3Kα/δ/γ，在无细胞试验中IC50为 39 nM/36 nM/23 nM，对PI3Kβ作用较低。Phase 1/2。

  • GNE-317 New

    GNE-317 是一种有效的，大脑渗透性 PI3K 抑制剂。

  • LY294002

    LY294002 是首个合成的已知抑制PI3Kα/δ/β的小分子，在无细胞测定中IC50分别为 0.5 μM/0.57 μM/0.97 μM；在溶液中比在Wortmannin中稳定，也能够阻断自噬体的形成。它不仅能够结合class I PI3Ks和其他PI3K相关的激酶，还能够结合一些与PI3K家族无关的新型靶点。

    Features:LY294002是选择性的, 可渗透细胞的特定PI3K抑制剂，可作用于酶的ATP结合位点，且抑制自体吞噬的螯合作用。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA)是一种选择性PI3K抑制剂，作用于Vps34和PI3Kγ，在 HeLa细胞中IC50分别为25 μM和60 μM；永久性抑制I型PI3K，但对III型PI3K的抑制是短暂的，也会阻断自噬体的形成。现配现用（加热助溶）。

  • Idelalisib (CAL-101, GS-1101)

    Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂，在无细胞试验中IC50为 2.5 nM；对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍，对p110δ的选择性是对 C2β，hVPS34，DNA-PK 和 mTOR的400到4000倍。

    Features:Calistoga 暗示 CAL-101治疗血液恶性肿瘤可能有更广泛的应用价值。

  • Wortmannin

    Wortmannin是一种首次命名的PI3K抑制剂，在无细胞试验中IC50为3 nM，对 PI3K 家族的选择性较低。也会抑制自噬体的形成，并有效抑制DNA-PK/ATM，在无细胞试验中IC50为16 nM和150 nM。

  • Dactolisib (BEZ235, NVP-BEZ235)

    Dactolisib (BEZ235, NVP-BEZ235) 是一种双重ATP竞争性 PI3K 和 mTOR 抑制剂，在无细胞试验中，抑制 p110α/γ/δ/β 和 mTOR(p70S6K) 的 IC50 分别为 4 nM /5 nM /7 nM /75 nM /6 nM。 在 3T3TopBP1-ER 细胞中抑制 ATR，IC50 为 21 nM，而对 Akt 和 PDK1 的抑制作用很弱。Phase 2。

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941) 是一种有效的PI3Kα/δ抑制剂，在无细胞试验中IC50为 3 nM，对p110β (11倍)和p110γ (25倍)具有适度的选择性。Phase 2。

  • Alpelisib (BYL719)

    Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂，在无细胞试验中IC50为 5 nM，对PI3Kβ/γ/δ具有极弱的作用。Phase 2。

Tags: 购买Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)供应商 | 采购Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)价格 | Buparlisib (BKM120, NVP-BKM120)生产 | 订购Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID